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Introduction
For hemodialysis of patients with renal
failure, vascular access is needed. This
is mainly achieved with a central venous
catheter or by creation of an arteriove-
nous shunt. Best results for the latter in
terms of functional duration and compli-
cation rates (infections, thrombosis) are
gained by using autologous veins [1, 2].
In the absence of a suitable vein, vari-
ous homologous, heterologous or pros-
thetic grafts are used [3]. At our insti-
tution, mainly expanded polytetraﬂuo-
roethylene (ePTFE)prostheseshave been
implanted for more than 15 years. Steno-
sis and thrombosis are frequent but can
be corrected in the majority of cases by
surgical thrombectomy and/or translu-
minal venous angioplasty [4, 5]. The
most serious factor is bacterial infection,
which is associated with high morbid-
ity and mortality [6–9]. Gram-positive
bacteria are the main cause of prosthetic
shunt graft infections and Staphylococ-
cus aureus is reported to be present in
60% [10] of cases. Major complications
(e.g. death or septic embolization to
bones, joints, endocardium and brain)
are found in 12% of infected grafts [10].
Many microorganisms can switch from
a free-living state to a sessile mode of
life, forming a bioﬁlm on surfaces [11].
The bioﬁlm is a polymer matrix con-
sisting of polysaccharides, proteins and
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DNA, which embeds the bacteria. This
environment shows increased tolerance
to antibiotics and resistance to phagocy-
tosis and other components of the body’s
defence system [12]. Shunt graft infec-
tions are therefore diﬃcult to treat and
so far, complete shunt graft explantation
as early as possible is the treatment of
choice.
In January 2014 we performed an in-
ternal audit on prosthetic shunt graft in-
fections carried out between December
1998 and December 2013 and found a
10.8% explantation rate due to infection.
In 74.3 % of cases S. aureus was involved.
Serious concern arose about the question
whether therewasanosocomialproblem.
We decided to perform a detailed assess-
ment and to include genetic techniques
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Fig. 18NumberofPTFE shuntgraft explantationsdue to infection itemized inyears after the implan-
tation (totalling 54)
Patients andmethods
Patients with implantation of a PTFE
shunt graft between 1 December 1998
and 31 December 2014 were included in
thestudy. Onlyprimaryshuntgrafts from
artery to vein were included, short shunt
grafts for corrective operations, such as
interpositions were excluded. Infections
of secondary shunt grafts from arter-
ies to old prostheses or from prosthe-
ses to vein were categorized as primary
shunt operation complications. Microbi-
ological specimens included blood cul-
tures and/or wound swabs. All shunt
graftswerecompletelyexplanted. Inmost
cases, a venous patch-plasty at the site of
the arterial anastomosis and direct clo-
sure at the site of the venous anastomo-
sis were performed. After explantation,
open wound management was carried
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Table 1 Bacterial spectrumof54 shuntgraft infections at theDepartmentofSurgery,Divisionof
Vascular Surgery,MUG, Austria
n 54
Samples with detection of monocultures infections with one strain 33
Staphylococcus aureus 26




Samples with co-infections with two strains 7
Staphylococcus aureus and Enterococcus 2
Coagulase negative Staphylococcus, Staphylococcus epidermidis 1
Staphylococcus aureus, Staphylococcus epidermidis 3
Corynebacterium spp.,Micrococcus sp 1
Samples with polymicrobial infections with four strains 2
Coagulase negative Staphylococcus, Staphylococcus epidermidis, Corynebact., Kleb-
siellia pneumoniae ESBL
1
Staphylococcus aureus, Enterococcus, Staphylococcus epidermidis, Klebsiellia oxytoca 1
Infections without strain detection 12
Table 3 Impact of independent inﬂuencing factors on shunt graft infection rates
Independent factor p-value
Sex 0.660
Institute for dialysis 0.064
Age 0.376
Inner coating of the PTFE prosthesis (none, carbon, heparin) 0.708
Implantation surgeon 0.810
Shunt position (upper extremity vs. lower) 0.537
out, sometimes with negative pressure
wound therapy. After achieving suﬃ-
cient granulation on a clean surface, sec-
ondarywoundclosurewasexecuted. Fol-
low-up was registered until 28 February
2015. Data were acquired retrospectively
from written reports in the hospital data
system, from the patients and from the
institutes performing dialysis. In 2014,
three cases with S. aureus underwent ge-
netic examination using the spa typing
method. Protein A is a surface protein
of the cell wall of S. aureus. It is en-
coded by the spa genewhich canbe typed
on the basis of the base sequence. Spa
types are recorded and provided by a
worldwide usable server project (Ridom
SpaServer [13]). Up to 12 January 2016,
a total of 15,573 diﬀerent spa types were
recorded by 668 registered users from 60
user countries (117 strain countries). In-
ﬂuencing factors were assessed with χ2-
test, Fisher’s exact test or logistic regres-
sionusing IBM®SPSS®Statistics 23.0.0.0.
All tests were two-sided and P-values be-
low 0.05 were regarded as signiﬁcant.
Results
From 1 December 1998 to 31 December
2014, a total of 1431 shunt operations
were performed at the Department of
Surgery, Division of Vascular Surgery,
MUG, Austria, 490 of which were PTFE
shunt graft implantations (shunt graft
rate 34.2 %). In total 54 cases had to be
excluded due to the exclusion criteria,
42.2% (184/436) had a carbonized inner
surface (Venaﬂo®, Carboﬂo®, C.R. Bard,
Inc. Corporate Oﬃce, Murray Hill, New
Jersey, USA), 20% (87/437) were plain
PTFE (Gore-Tex® vascular graft, stan-
dard walled or Gore-Tex® vascular graft,
thin-walled ringed or unringed, W.L.



























Susceptibility of detected S. aureus to
antibiotics R: resistant, S: susceptible
Gore & Associates, Inc. Medical Prod-
ucts Division, Flagstaﬀ, Arizona, USA).
All patients received a single shot of
antibiotic prophylaxis and in most cases
vancomycin 1 gwas administered 30min
prior to skin incision. Of the prostheses
14.0 % (61/436) had to be explanted
for several reasons: three for shunt
aneurysms, two for large hematomas,
one after renal transplantation and one
for acute rupture. The remaining 54
shunt grafts were explanted due to in-
fection. Nearly half of the infections
developed in the ﬁrst year (. Fig. 1) but
explantation was even peformed 8, 10
and 14 years after surgery with shunt
grafts that had not been used for years.
In 61.1 % (33/54) of cases, monobac-
terial cultures could be found (. Table 1)
and in 13.0 % (7/54) 2 diﬀerent bacteria
were detected. In 3.7 % (2/54), 4 diﬀer-
ent bacteria were identiﬁed and in 22.2 %
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Impact of Staphylococcus aureus protein A (spa) genetic typing in cases of prosthetic shunt graft
infections
Abstract
Introduction. In January 2014 an internal
audit was performed at the department of
surgery, division of vascular surgery of the
Medical University Graz, Austria, to assess the
short and long-term outcomes of prosthetic
shunt graft implantations performed between
December 1998 and December 2013. A 10.8 %
explantation rate due to graft infection was
detected. The majority of the cases were
associated with Staphylococcus aureus. The
aim of this study was to clarify whether this
constitutes a nosocomial problem.
Patients andmethods. Between December
1998 and December 2014 a total of 490
prosthetic shunt grafts were implanted. After
exclusion of 54 cases, 436 shunts remained
for statistical analysis. Genetic analysis (spa
typing) was acquired from three new cases
with involvement of S. aureus in 2014. The
impact of several factors (e.g. sex, institute for
dialysis, age, type of prosthesis, implantation
surgeon and position of shunt) on the shunt
graft infection rate was statistically analyzed.
Results. Of the prostheses 14.0% (61 out of
436) had to be explanted of which 12.4 %
(54/436) were due to infection. In 77.8%
(42/54) bacteria were found in blood and/or
wound cultures. Staphylococcus aureus
was present in 76.2 % (32/42) of the cases
with detected bacteria and in all cases was
sensitive to methicillin. The infection rate
was not signiﬁcantly dependent on any of
the investigated factors; however, the factor
“institute for dialysis” had a remarkable
p-value of 0.060 with the infection rate
ranging from 8.5% to 18.2 % depending
on the institution. Three diﬀerent S. aureus
protein A (spa) types were found: t015, t359,
t6265. The detection of three diﬀerent spa
types means that these patients had diﬀerent
sources of S. aureus so that a nosocomial
problem is very unlikely.
Conclusion. Genetic typing of spa is a
suitable technique for distinguishing between
nosocomial and community acquired sources
of prosthetic shunt graft infections.
Keywords
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Bedeutung der genetischen Typisierung von Protein A aus Staphylococcus aureus bei
Shuntprotheseninfektion
Zusammenfassung
Einleitung. Im Januar 2014 wurde an der
Universitätsklinik für Chirurgie, Klinische
Abteilung für Gefäßchirurgie, Medizinische
Universität Graz, Österreich, ein internes audit
über kurz- und langfristige Ergebnisse der im
ZeitraumDezember 1998 bis Dezember 2013
implantierten Shuntprothesen durchgeführt.
Eine 10,8 %ige Explantationsrate aufgrund
einer Infektion der Transplantate wurde
festgestellt. Die Mehrzahl der Fälle war mit
Staphylococcus aureus assoziiert. Das Ziel
unserer Studie war es, zu klären, ob ein
nosokomiales Problem vorliegt oder nicht.
Patienten und Methoden. Zwischen
Dezember 1998 und Dezember 2014 wurden
490 Shuntprothesen implantiert. Nach
Ausschluss von 54 Fällen blieben 436 Shunts
für die statistischeAnalyse. Drei neue Fälle aus
dem Jahr 2014 mit Beteiligung von S. aureus
konnten genetisch analysiert werden (spa-
Typisierung). Der Einﬂuss verschiedener Fakto-
ren (Geschlecht, Dialysezentrum, Alter, Art der
Prothese, Chirurg der Implantation, Position
des Shunt) auf die Shuntinfektionsratewurde
statistisch ausgewertet.
Ergebnisse. Ein Anteil von 14,0 % (61/436)
der Prothesen musste explantiert werden,
12,4% (54/436) aufgrund einer Infektion. In
77,8% (42/54) dieser Fälle wurden Bakterien
in Blut- und/oder Wundkulturen gefunden.
S. aureus wurde in 76,2 % (32/42) der Fälle
mit positiver Bakterienkultur nachgewiesen,
in allen Fällen war eine Empﬁndlichkeit
gegenüber Methicillin vorhanden. Die
Infektionsrate war nicht signiﬁkant abhängig
von den untersuchten Faktoren, jedoch
hatte der Faktor „Dialysezentrum“ einen
bemerkenswerten p-Wert von 0,060mit einem
Infektionsratenbereich von 8,5 bis 18,2 % pro
Einrichtung. Es wurden drei verschiedene
S. aureus spa-Typen gefunden: t015, t359,
t6265. Drei ungleiche spa-Typen bedeuten,
dass diese Patienten verschiedene S. aureus
Quellen hatten, so dass ein nosokomiales
Problem sehr unwahrscheinlich ist.
Schlussfolgerung. Die spa-Typisierung
ist eine geeignete Technik, um zwischen




Shuntprothese · Infektion · Staphylococcus
aureus · Spa-Typisierung · Nosokomial
(12/54) bacterial cultures stayed sterile.
S. aureuswas present in 76.2% (32/42) of
cases with detected bacteria and nearly
all isolateswere resistant to penicillin and
ampicillin susceptibility and susceptible
to all other tested antibiotics (. Table 2).
None of the isolates were methicillin-re-
sistant S. aureus (MRSA).
A total of 3 S. aureus strains from
2014 underwent spa typing. Three dif-
ferent types were found (worldwide fre-
quency according to Ridom SpaServer):
t015 (1.12 %), t359 (0.17 %) and t6265
(<0.01%).
We investigated inﬂuencing factors
(. Table 3) but did not ﬁnd any to be
signiﬁcant. The “dialysis institute” factor
had a remarkable p-value of 0.064. In
one of them, the shunt graft explantation
rate due to infection was 18.2 %, whereas
it was 8.5 % and 9.6% for the others.
Discussion and conclusion
The primary goal of our study was to
clarify whether there is a nosocomial
problem. Spa typing of 3 cases from
2014 revealed 3 diﬀerent genetic types,
so they must have arisen from diﬀerent
sources and therefore anosocomial prob-
lem is veryunlikely. Spa typing is a typing
method with a very high discriminatory
index of 0.87 comparable to repetitive
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sequence-based PCR (0.88) and multi-
locus sequence typing (0.84). It is bet-
ter than pulsed-ﬁeld gel electrophoresis
(0.76) and staphylococcal cassette chro-
mosome mec typing (0.60) [14]. Spa
typing therefore seems to be a good way
to discriminate between nosocomial and
community-acquired shunt graft infec-
tions.
For the chronological course of shunt
graft explantations (. Fig. 1), an expo-
nential curve caneasilybeadjustedwhich
is typical for nearly every biological pro-
cess. If our shunt graft infections were
a problem caused by the primary opera-
tion, nearly all explantations should have
occurred in the ﬁrst year; therefore we
assume that the shunt graft patients were
S. aureus carriers and furthermore that
every S. aureus carrier will experience
shunt graft infections over time just as a
matter of chance. This must be proven
in a separate trial.
In hemodialysis patients, nasal car-
riage ofS. aureus is a risk factor for thede-
velopment of S. aureus bacteremia. Nasal
mupirocin ointment can be used to suc-
cessfully eradicate S. aureus from nasal
carriage and is able to reduce the inci-
dence of S. aureus bacteremia by 75.25%
[15–17]; therefore we will implement
nasal eradication of S. aureus as part
of our standard procedures and moni-
tor the results thoroughly. On the other
hand, there were remarkable diﬀerences
in shunt infection rates between the in-
stitutions which performed dialysis. We
have contacted the institution with the
unexpectedly high rate but have not yet
found a reason for the diﬀerence. We
assume diﬀerent disinfection techniques
to be responsible for that phenomenon
but have not yet been able to prove it.
In 22.2 % of our cases we did not de-
tect any strain. This might be due to the
fact that in cases of suspected infection,
antibiotic treatment is induced immedi-
ately. Bacterial cultures from blood or
the surgical wound might remain sterile
if the time interval between induction of
antibiotic treatment and surgery is long
enough. Nevertheless, bacteria are still
present in the bioﬁlm of the prosthe-
sis. In recent years we have therefore
changed our strategy and always send a
part of the prosthesis for microbiolog-
ical investigation. We can recommend
this technique most notably if the tissue
around the prosthesis looks unsuspicious
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